ReviewCureus2020
Tumor Lysis Syndrome in Solid Tumors: A Comprehensive Literature Review, New Insights, and Novel Strategies to Improve Outcomes.
Review in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response.Journal for immunotherapy of cancer · 2026Article
- Pathology associated with human CAR T cell administration in NOD.Cg-Veterinary pathology · 2026Article
- Fatal Tumor Lysis Syndrome Induced by Pembrolizumab in Advanced Renal Pelvis Cancer.IJU case reports · 2026Article
- An uncommon encounter with tumor lysis syndrome in colorectal cancer.German medical science : GMS e-journal · 2026Article
- Pancreatic tumor microenvironment reprogramming via alloantigenexpressing virotherapy elicits tumor rejection and improves immunotherapy response.bioRxiv : the preprint server for biology · 2025Article
- Article
- An Overview of the Management of Electrolyte Emergencies and Imbalances in Cancer Patients.Journal of the advanced practitioner in oncology · 2025Review
- Atypical Presentation of Tumor Lysis Syndrome Complicated by Rasburicase-Induced Methemoglobinemia.Cureus · 2025Article
- Tumor Lysis Syndrome in a Patient with BRAFInternal medicine (Tokyo, Japan) · 2025Article
- Case Report: Tumor lysis syndrome in advanced, massive hepatocellular carcinoma with main portal vein invasion following atezolizumab plus bevacizumab therapy.Frontiers in oncology · 2025Article
- Novel immunotherapeutic approaches in gastric cancer.Precision clinical medicine · 2024Review
- Tumour lysis syndrome.Nature reviews. Disease primers · 2024Review
- Fetal liver CD34Stem cell research & therapy · 2024Article
- Spontaneous tumor lysis syndrome (STLS) during biopsy for burkitt lymphoma: a case report.BMC pediatrics · 2024Article
- Beyond the Expectation: Pembrolizumab-Associated Tumor Lysis Syndrome in Metastatic Gastric Adenocarcinoma.Cureus · 2023Article
- A case of disseminated intravascular coagulation following tumour lysis syndrome due to small cell carcinoma of the lung.Respirology case reports · 2023Article
- Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases.Cureus · 2022Review
- Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.Journal of managed care & specialty pharmacy · 2022Article
- Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature.Journal of medical case reports · 2022Review
- Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor lysis syndrome (TLS) is a life-threatening oncological condition that is typically characterized by metabolic derangements that are often labeled as an acute kidney injury. The recent advancement in cancer treatment has led to the mounting rate of TLS in solid tumors that were previously rarely linked to this complication. Given that its prognosis is dismal, it is essential to increase recognition of this condition by describing more sensitive markers. Currently, the management of TLS is mainly supportive due to the lack of specific therapy targeting its specific pathology. This review aims to summarize the most recent literature on the underlying mechanism of TLS and the potential implications for novel TLS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.